BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$70.10 USD
-0.19 (-0.27%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $70.22 +0.12 (0.17%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.10 USD
-0.19 (-0.27%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $70.22 +0.12 (0.17%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth B Momentum B VGM
Zacks News
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
by Zacks Equity Research
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BMRN or MYGN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BMRN vs. MYGN: Which Stock Is the Better Value Option?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)
by Zacks Equity Research
BioMarin (BMRN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Ascendis Soars on Encouraging Data From Dwarfism Drug Study
by Zacks Equity Research
ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
by Zacks Equity Research
BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
Why Is BioMarin (BMRN) Up 5.4% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo
by Zacks Equity Research
Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo are part of the Zacks Screen of the Week article.
Bet on These 5 Stocks With Upgraded Broker Ratings Right Now
by Swayta Shah
Brokers have deeper insights into stocks and the macroeconomic backdrop. One must follow broker rating upgrades to pick stocks like WWW, BMRN, DDOG, PGR & KVYO.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in BioMarin (BMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioMarin (BMRN) stock based on the movements in the options market lately.
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
by Zacks Equity Research
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
Here's Why You Should Invest in BioMarin (BMRN) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
by Zacks Equity Research
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 68.42% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -3.45% and 9.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the second quarter of 2024 in both the United States and International segments.